DEFA14A: Dynavax Rejects Glass Lewis Recommendations, Defends Board and Strategy Ahead of Annual Meeting

Dynavax Technologies Corporation issued a statement on June 5, 2025, disagreeing with Glass Lewis's recommendations against two board members, asserting its successful vaccine-focused strategy and strong financial position.

Summary

• Dynavax Technologies Corporation responded to a report issued by Glass, Lewis & Co. on June 3, 2025, concerning the company's 2025 Annual Meeting of Stockholders.
• The company acknowledged Glass Lewis's recognition of its 2019 strategic pivot toward vaccines, which has driven meaningful stockholder value creation.
• Dynavax reported a 203% total return over the last five years as of April 17, 2025, significantly outperforming peers and relevant indices.
• The company firmly disagreed with Glass Lewis's recommendation against Brent MacGregor and Scott Myers, stating they are instrumental to Dynavax's success and bring critical experience.
• Dynavax criticized Glass Lewis's liquidity analysis, arguing it misinterprets prudent capital allocation as excessive conservatism and fails to account for anticipated capital needs.
• The company characterized Glass Lewis's view on board representation for an investor (Deep Tracks) as overlooking concerted efforts to reach a reasonable compromise, believing Deep Tracks pursues a value-destructive strategy.
• Dynavax stated that Deep Tracks' nominees are underqualified, and their claimed skills are already well-represented on the current Board.
• Specific concerns were raised about Brett Erkman's lack of experience and rigid alignment with Deep Tracks' narrow, short-term agenda.
• Donald Santel was noted to lack vaccine-specific expertise, with his public C-suite experience ending ten years prior, and his background not being additive to the existing Board's skills.
• CEO Ryan Spencer affirmed that Dynavax has the 'right strategy, the right leadership and a proven record of delivering results'.

Sentiment

Score: 8

Explanation: The document conveys a strongly positive sentiment from Dynavax's perspective, robustly defending its successful strategy, strong financial performance, and the expertise of its board members against external criticism and activist shareholder proposals.

Positives

• The 2019 strategic pivot toward vaccines has driven meaningful stockholder value creation.
• Achieved a 203% total return over the last five years (as of April 17, 2025), significantly outperforming peers and relevant indices.
• The Board is strong and deep, having been significantly refreshed with directors possessing extensive, relevant expertise in vaccine development, commercialization, and public company leadership.
• Brent MacGregor and Scott Myers are considered instrumental to the company's success and bring critical experience and leadership.
• The company believes it has more cash than its peers, indicating a strong liquidity position.
• Management asserts the company has the 'right strategy, the right leadership and a proven record of delivering results'.

Negatives

• Disagreement with Glass Lewis's recommendation against the re-election of Brent MacGregor and Scott Myers to the Board.
• Glass Lewis's liquidity analysis is considered flawed, misinterpreting prudent capital allocation as excessive conservatism.
• Glass Lewis's characterization of the company's responsiveness to stockholder feedback is seen as mistaken, overlooking efforts to compromise with Deep Tracks.
• The company believes Deep Tracks is pursuing a value-destructive strategy.
• Deep Tracks' nominees are considered underqualified and their skills redundant to the existing Board.
• Concerns were raised about Brett Erkman's lack of experience and rigid alignment with Deep Tracks' short-term agenda.
• Donald Santel lacks vaccine-specific expertise and recent public C-suite experience, not adding to the Board's existing skills.

Risks

• Replacing any Dynavax directors with Deep Tracks' underqualified nominees would disrupt the momentum of the company's successful long-term strategy.
• Such changes could put stockholder value at risk.
• Deep Tracks' narrow agenda prioritizes short-term gain at the expense of long-term value.

Future Outlook

Dynavax anticipates continued success and value creation, asserting that its current strategy, leadership, and board composition are essential for delivering future results.

Management Comments

• "We firmly disagree with the reports conclusion, as the individuals Glass Lewis recommends against, Brent MacGregor and Scott Myers, have been instrumental to the success the report acknowledges and bring critical experience and leadership that are essential to Dynavaxs continued success and value creation."
• "Glass Lewis recommendation seems rooted in a liquidity analysis that simply proves we have more cash than our peers; this fails to account for our anticipated capital needs and interprets prudent capital allocation as excessive conservatism."
• "Replacing any Dynavax directors with Deep Tracks underqualified nominees would disrupt the momentum of our clearly successful long-term strategy and put stockholder value at risk."
• "Dynavax has the right strategy, the right leadership and a proven record of delivering results." Ryan Spencer, Chief Executive Officer.

Industry Context

This document highlights Dynavax's focus on the vaccine segment of the biotechnology and pharmaceutical industry, showcasing its strong performance relative to broader market trends and competitors. The ongoing dispute with Glass Lewis and Deep Tracks reflects common corporate governance challenges, including shareholder activism and debates over board composition and strategic direction within public companies.

Comparison to Industry Standards

• Dynavax's 203% total return over five years (as of April 17, 2025) is stated to have 'far outperforming peers and relevant indices', indicating strong performance relative to industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the outcome of the proxy contest, which will determine the composition of the Board and potentially influence the company's long-term strategy and value creation. The company emphasizes its track record of 'meaningful stockholder value creation' and warns against 'value-destructive strategy' by Deep Tracks.
• Board of Directors: The re-election of specific directors is at stake, impacting the continuity of leadership and strategic oversight.

Next Steps

• The 2025 Annual Meeting of Stockholders is the next key event where the matters discussed, including board member elections, will be addressed.

Key Dates

Recommendation

Keywords

Dynavax Technologies Corporation, SEC filing, DEFA14A, Proxy Statement, Glass Lewis, Annual Meeting, Stockholders, Vaccines, Corporate Governance, Board of Directors, Shareholder Value, Strategic Pivot, Total Return, Capital Allocation, Deep Tracks